Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Shares Shorted: Short Interest Up 223.8% in October

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 12,328 shares, an increase of 223.8% from the September 30th total of 3,807 shares. Based on an average trading volume of 55,739 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Price Performance

Shares of RGNT stock traded up $0.02 during trading hours on Friday, hitting $1.38. 13,326 shares of the company’s stock traded hands, compared to its average volume of 1,663,442. The stock’s 50 day simple moving average is $1.79 and its 200 day simple moving average is $2.93. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last issued its earnings results on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a clinical-stage medical device company focused on developing regenerative solutions for cartilage repair and other orthopedic applications. The company’s work is centered on biomaterials designed to support the restoration of damaged or diseased tissue.

Regentis’ lead product is GelrinC, an implantable hydrogel intended to treat focal cartilage defects, particularly in the knee. The product is designed to fill the damaged area and provide a scaffold that may support the body’s natural cartilage-repair processes.